| Similar Articles |
|---|
 |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference.   |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
February 10, 2003
Malorye Branca |
Conquering Infinity with Chemical Genetics Harvard superchemist Stuart Schreiber defines the convergence of chemistry and biology. Now the field of chemical genetics is heading toward the clinic. |
The Motley Fool
June 2, 2011
Luke Timmerman |
Infinity Dares to Think Big Against Pancreatic Cancer, Prepares to Show Early Results This Weekend Infinity Pharmaceuticals' top execs sometimes get strange looks when they say they are developing a new drug for pancreatic cancer. Is this a smart use of the company's time and resources? |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
Bio-IT World
March 17, 2004 |
Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006. |
Bio-IT World
February 2006 |
News Blast Hit-to-Lead... Whole Genome... Gleevec Resistance... |
Bio-IT World
October 2006
John Russell |
Entelos Makes Post IPO Report After netting $16.6 million in a public offering on London's Alternative Investment Market last April, biosimulator Entelos released interim six-month results. |
Bio-IT World
Jul/Aug 2006
Kevin Davies |
Beyond the Last Chromosome About 700 attendees gathered Beyond Genome 2006, one of Cambridge Healthtech Institute's flagship conferences, to discuss the major technology trends in postgenomic biology, including systems biology, RNAi, proteomics, and personalized medicine. |
Bio-IT World
February 18, 2004 |
The Quest for Complex Genes Genetic sleuths are homing in on genes for complex diseases with the help of new, and some not so new, tools and strategies. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test. |
Bio-IT World
June 2006
Kevin Davies |
HapMap Project Prepares for Phase II Release The official release of the Phase II HapMap data will provide a publicly available trove of information on human genetic variation across populations that will reveal insights into the genetic basis of human disease and individual response to pharmaceuticals. |
Bio-IT World
January 13, 2003
Jennifer Lorenzetti |
Taking Data Storage to Infinity -- and Beyond Perlegen Sciences has made important advances in resequencing DNA and identifying SNPs (single nucleotide polymorphisms), to the point that an entire human genome can be deduced in about 10 days. But it requires storing an extraordinary amount of data -- here's how it's done. |
Bio-IT World
May 2006
John Russell |
Buyers Panel: What Biopharma Wants What does big (and at least one little) biopharma really want from technology providers? That was the theme of an entertaining session at Bio-IT World's Expo, featuring top IT and informatics executives from Merck, Lilly, Pfizer, Novartis, and Infinity Pharmaceuticals. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
Bio-IT World
January 21, 2005 |
Best Practices 2005: Strut Your Stuff Organizations are invited to strut their stuff for Bio*IT World's annual awards program. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
Bio-IT World
June 12, 2002
Kevin Davies |
Variations on a Theme Researchers at Genaissance Pharmaceuticals have outlined the path to creating a comprehensive map of human genomic variation that should ultimately reveal the genetic underpinnings of common diseases. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
The Motley Fool
July 21, 2011 |
Avoid This Biotech Stock Our investing community's latest stock to avoid: Infinity Pharmaceuticals. |
